Vistagen Therapeutics (VTGN) Short Interest Ratio & Short Volume $2.32 -0.04 (-1.69%) As of 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Vistagen Therapeutics Short Interest DataVistagen Therapeutics (VTGN) has a short interest of 533,800 shares, representing 2.04% of the float (the number of shares available for trading by the public). This marks a 2.14% increase in short interest from the previous month. The short interest ratio (days to cover) is 4.2, indicating that it would take 4.2 days of the average trading volume of 171,442 shares to cover all short positions.Current Short Interest533,800 sharesPrevious Short Interest522,600 sharesChange Vs. Previous Month+2.14%Dollar Volume Sold Short$1.35 millionShort Interest Ratio4.2 Days to CoverLast Record DateMay 31, 2025Outstanding Shares28,862,000 sharesFloat Size26,110,000 sharesShort Percent of Float2.04%Today's Trading Volume106,131 sharesAverage Trading Volume171,442 sharesToday's Volume Vs. Average62% Short Selling Vistagen Therapeutics? Sign up to receive the latest short interest report for Vistagen Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartVTGN Short Interest Over TimeVTGN Days to Cover Over TimeVTGN Percentage of Float Shorted Over Time Vistagen Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/31/2025533,800 shares $1.35 million +2.1%2.0%4.2 $2.52 5/15/2025522,600 shares $1.20 million +9.7%2.0%3.9 $2.30 4/30/2025476,300 shares $1.11 million -8.0%1.8%3.5 $2.34 4/15/2025517,500 shares $1.15 million -3.4%2.0%3.5 $2.22 3/31/2025535,600 shares $1.34 million -9.9%2.1%3.2 $2.50 3/15/2025594,700 shares $1.61 million -8.6%2.3%2.5 $2.70 2/28/2025650,400 shares $1.76 million -2.9%2.5%2.6 $2.70 2/15/2025669,800 shares $1.99 million -10.0%2.6%2.6 $2.97 1/31/2025744,400 shares $2.15 million +13.1%3.0%2.8 $2.89 1/15/2025658,100 shares $1.95 million +46.2%2.6%2.4 $2.97 Get the Latest News and Ratings for VTGN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Vistagen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/2024450,000 shares $1.33 million +9.9%1.8%1.6 $2.95 12/15/2024409,600 shares $995.33 thousand -3.7%1.6%1.7 $2.43 11/30/2024425,500 shares $1.21 million -0.5%1.7%2.1 $2.84 11/15/2024427,500 shares $1.12 million -19.1%1.7%2.3 $2.63 10/31/2024528,200 shares $1.63 million -18.1%2.1%3.3 $3.08 10/15/2024644,700 shares $1.88 million -5.2%2.7%4.7 $2.92 9/30/2024679,900 shares $2.05 million -7.9%2.8%5.7 $3.01 9/15/2024738,300 shares $2.43 million -6.7%3.0%6.8 $3.29 8/31/2024791,300 shares $2.76 million -4.3%3.3%7.3 $3.49 8/15/2024826,700 shares $2.79 million +8.2%3.4%7.3 $3.38 7/31/2024764,100 shares $2.62 million -4.5%3.1%6.8 $3.43 7/15/2024799,800 shares $3.13 million -7.8%3.3%6.1 $3.91 6/30/2024867,600 shares $3.02 million -2.5%3.6%6.1 $3.48 6/15/2024889,500 shares $3.13 million -11.1%3.7%4.6 $3.52 5/31/20241,000,000 shares $3.86 million -5.7%4.1%4.9 $3.86 5/15/20241,060,000 shares $4.87 million -10.2%4.4%4.6 $4.59 4/30/20241,180,000 shares $5.70 million -8.5%4.9%4.6 $4.83 4/15/20241,290,000 shares $6.13 million +0.8%5.3%4.9 $4.75 3/31/20241,280,000 shares $6.76 million -3.8%5.3%4.4 $5.28 3/15/20241,330,000 shares $5.39 million -8.9%5.5%4.7 $4.05 2/29/20241,460,000 shares $7.46 million -15.1%6.0%3.6 $5.11 2/15/20241,720,000 shares $9.32 million +27.4%7.1%4.1 $5.42 1/31/20241,350,000 shares $6.45 million +16.4%5.6%2.6 $4.78 1/15/20241,160,000 shares $6.32 million -28.8%4.8%2.1 $5.45 12/31/20231,630,000 shares $8.38 million +37.0%6.7%2.7 $5.14 12/15/20231,190,000 shares $5.93 million -4.8%4.9%1.8 $4.98 11/30/20231,250,000 shares $4.49 million -21.4%5.1%2.1 $3.59 11/15/20231,590,000 shares $5.23 million +2.6%6.4%2.7 $3.29 10/31/20231,550,000 shares $4.93 million +14.8%7.0%1.4 $3.18 10/15/20231,350,000 shares $4.64 million +61.6%6.1%0.7 $3.44Billionaires are piling into this gold investment (Ad)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scrambling to buy gold coins and bars. But some savvy investors have used a different way to profit from gold bull runs — a special investment with a long history of making 13 times … 21 times … 157 times … even a surprising 1,000 times more than physical gold. Click here to see how to make the most out of this historic gold bull market. 9/30/2023835,300 shares $4.38 million +16.8%3.5%0.4 $5.24 9/15/2023715,100 shares $4.25 million -31.9%7.7%0.4 $5.95 8/31/20231,050,000 shares $5.60 million -18.0%11.3%0.6 $5.33 8/15/20231,280,000 shares $8.04 million +132.2%13.8%0.7 $6.28 7/31/2023551,300 shares $1.00 million +18.1%7.0%0.4 $1.82 7/15/2023467,000 shares $826.59 thousand +36.3%6.0%2.3 $1.77 6/30/2023342,600 shares $640.66 thousand -50.2%4.4%1.7 $1.87 6/15/2023687,500 shares $1.43 million +72.2%9.5%3.2 $2.08 5/31/2023399,200 shares $1.70 million -96.8%N/A2.3 $4.26 5/15/202312,450,000 shares $1.75 million -12.0%N/A3.6 $0.14 4/30/202314,150,000 shares $1.98 million -10.6%N/A3 $0.14 4/15/202315,820,000 shares $2.19 million +25.0%N/A2.9 $0.14 3/31/202312,660,000 shares $1.58 million +47.7%N/A2.1 $0.12 3/15/20238,570,000 shares $1.31 million +17.4%N/A1.2 $0.15 2/28/20237,300,000 shares $1.28 million -14.9%N/A1 $0.18 2/15/20238,580,000 shares $1.70 million -15.8%N/A1.1 $0.20 1/31/202310,190,000 shares $2.64 million -17.8%N/A1.5 $0.26 1/15/202312,400,000 shares $1.98 million -19.7%N/A2.1 $0.16 12/30/202215,440,000 shares $1.59 million +36.9%N/A2.5 $0.10 12/15/202211,280,000 shares $1.27 million +24.2%N/A2.1 $0.11 11/30/20229,080,000 shares $1.25 million -1.2%N/A1.7 $0.14 11/15/20229,190,000 shares $1.46 million +13.7%N/A1.5 $0.16 10/31/20228,080,000 shares $1.07 million +26.5%4.6%0.9 $0.13 10/15/20226,390,000 shares $713.12 thousand +12.9%3.6%0.5 $0.11 9/30/20225,660,000 shares $860.89 thousand +18.4%3.2%0.4 $0.15 9/15/20224,780,000 shares $916.33 thousand -12.8%2.7%0.3 $0.19 8/31/20225,480,000 shares $1.01 million -13.3%3.1%0.4 $0.18 8/15/20226,320,000 shares $995.40 thousand -30.1%4.1%0.5 $0.16 7/31/20229,040,000 shares $1.29 million -46.1%5.8%1.1 $0.14 7/15/202216,770,000 shares $13.08 million +16.1%10.8%3 $0.78 6/30/202214,440,000 shares $12.71 million +2.1%9.3%11.8 $0.88 6/15/202214,150,000 shares $13.35 million +30.7%8.8%10.7 $0.94 5/31/202210,830,000 shares $12.45 million +1.2%6.8%7.3 $1.15 5/15/202210,700,000 shares $12.20 million +0.1%6.7%7.2 $1.14 4/30/202210,690,000 shares $13.58 million +6.2%6.7%6.9 $1.27 4/15/202210,070,000 shares $16.31 million -2.4%6.3%6.3 $1.62 3/31/202210,320,000 shares $12.80 million -10.7%6.4%6.8 $1.24 3/15/202211,560,000 shares $13.18 million -2.3%7.2%8.3 $1.14 2/28/202211,830,000 shares $16.56 million +1.7%7.5%9.8 $1.40 2/15/202211,630,000 shares $18.61 million -0.5%7.3%9.3 $1.60 1/31/202211,690,000 shares $19.05 million +2.4%7.6%8.9 $1.63 1/15/202211,420,000 shares $19.87 million +2.2%7.4%9 $1.74 12/31/202111,170,000 shares $21.78 million +1.6%N/A9.1 $1.95 12/15/202110,990,000 shares $20.44 million +3.0%7.2%9.1 $1.86 11/30/202110,670,000 shares $20.59 million +3.3%7.0%8.8 $1.93 11/15/202110,330,000 shares $22.21 million -7.1%6.8%9 $2.15 10/29/202111,120,000 shares $25.46 million -4.6%7.7%10.4 $2.29 10/15/202111,650,000 shares $27.84 million -3.6%8.0%11.3 $2.39 9/30/202112,080,000 shares $33.10 million +29.5%8.3%11.1 $2.74 9/15/20219,330,000 shares $27.24 million -6.5%6.4%5.2 $2.92Get Ready for Elon Musk’s BIGGEST Comeback Yet (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. Click here to see why Tesla's about to prove everyone wrong... again. 8/31/20219,980,000 shares $30.34 million -8.4%6.9%5.2 $3.04 8/13/202110,890,000 shares $30.17 million -5.7%7.7%5.1 $2.77 7/30/202111,550,000 shares $30.72 million -1.4%7.9%4.2 $2.66 7/15/202111,710,000 shares $33.14 million -5.1%6.9%4 $2.83 6/30/202112,340,000 shares $38.87 million +88.7%7.3%4.2 $3.15 6/15/20216,540,000 shares $18.12 million -3.0%3.9%2.9 $2.77 5/28/20216,740,000 shares $17.46 million +2.9%4.0%3.1 $2.59 5/14/20216,550,000 shares $13.95 million +3.8%N/A2.8 $2.13 4/30/20216,310,000 shares $15.21 million +2.8%N/A2.1 $2.41 4/15/20216,140,000 shares $12.89 million -1.4%N/A1.9 $2.10 3/31/20216,230,000 shares $13.33 million -32.5%N/A1.8 $2.14 3/15/20219,230,000 shares $21.69 million +8.5%N/A2.1 $2.35 2/26/20218,510,000 shares $18.81 million +62.1%N/A2 $2.21 2/12/20215,250,000 shares $10.40 million -2.6%N/A1.3 $1.98 1/29/20215,390,000 shares $11.16 million +0.4%N/A2.1 $2.07 1/15/20215,370,000 shares $12.46 million +54.3%N/A2.3 $2.32 12/31/20203,480,000 shares $6.16 million +48.7%8.3%1.9 $1.77 12/15/20202,340,000 shares $1.75 million -18.5%N/A1.7 $0.75 11/30/20202,870,000 shares $2.21 million +2.9%N/A4.4 $0.77 10/30/20202,900,000 shares $2.18 million -9.4%N/A2.8 $0.75 10/15/20203,200,000 shares $2.44 million +27.5%N/A1.8 $0.76 9/30/20202,510,000 shares $1.75 million -17.7%N/A1.1 $0.70 9/15/20203,050,000 shares $1.99 million -9.0%N/A1.3 $0.65 8/31/20203,350,000 shares $2.35 million +3.1%N/A1.4 $0.70 8/14/20203,250,000 shares $2.46 million +2.9%N/A1.3 $0.76 7/31/20203,160,000 shares $2.94 million +97.5%N/A1.4 $0.93 7/15/20201,600,000 shares $863.20 thousand -10.6%N/A1.1 $0.54 6/30/20201,790,000 shares $943.51 thousand +45.5%N/A1.9 $0.53 6/15/20201,230,000 shares $661.00 thousand -3.9%3.0%1.5 $0.54 VTGN Short Interest - Frequently Asked Questions What is Vistagen Therapeutics' current short interest? Short interest is the volume of Vistagen Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 31st, traders have sold 533,800 shares of VTGN short. 2.04% of Vistagen Therapeutics' shares are currently sold short. Learn More on Vistagen Therapeutics' current short interest. What is a good short interest ratio for Vistagen Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VTGN shares currently have a short interest ratio of 4.0. Learn More on Vistagen Therapeutics's short interest ratio. Which institutional investors are shorting Vistagen Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Vistagen Therapeutics: Caption Management LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Vistagen Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.04% of Vistagen Therapeutics' floating shares are currently sold short. Is Vistagen Therapeutics' short interest increasing or decreasing? Vistagen Therapeutics saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 533,800 shares, an increase of 2.1% from the previous total of 522,600 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Vistagen Therapeutics' float size? Vistagen Therapeutics currently has issued a total of 28,862,000 shares. Some of Vistagen Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Vistagen Therapeutics currently has a public float of 26,110,000 shares. How does Vistagen Therapeutics' short interest compare to its competitors? 2.04% of Vistagen Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Vistagen Therapeutics: Immutep Limited (2.93%), 2seventy bio, Inc. (5.37%), Inozyme Pharma, Inc. (8.49%), Cardiff Oncology, Inc. (37.39%), Foghorn Therapeutics Inc. (3.94%), Amarin Co. plc (2.42%), Lifecore Biomedical, Inc. (7.10%), Esperion Therapeutics, Inc. (13.54%), DBV Technologies S.A. (0.08%), MediWound Ltd. (12.82%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), Strategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks. What does it mean to sell short Vistagen Therapeutics stock? Short selling VTGN is an investing strategy that aims to generate trading profit from Vistagen Therapeutics as its price is falling. VTGN shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Vistagen Therapeutics? A short squeeze for Vistagen Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VTGN, which in turn drives the price of the stock up even further. How often is Vistagen Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VTGN, twice per month. The most recent reporting period available is May, 31 2025. More Short Interest Resources from MarketBeat Related Companies Immutep Short Interest 2seventy bio Short Interest Inozyme Pharma Short Interest Cardiff Oncology Short Interest Foghorn Therapeutics Short Interest Amarin Short Interest Lifecore Biomedical Short Interest Esperion Therapeutics Short Interest DBV Technologies Short Interest MediWound Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VTGN) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vistagen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vistagen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VTGN Stock Free VTGN Stock Alerts